After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Intellia Therapeutics Inc is $3.15B. A total of 3.19 million shares were traded on the day, compared to an average of 1.57M shares.
Insider Activity
Insider trades can also provide insight into a stock’s future direction. During the recent three months, NTLA has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 18 BUYs and 6 SELLs from insiders. Insiders purchased 313,877 shares during that period but sold 8,845.
In the most recent transaction, Sepp-Lorenzino Laura sold 2,275 shares of NTLA for 28.87 per share on Jan 08. After the transaction, the EVP, Chief Scientific Officer now owns 43,927 company shares. In a previous transaction on Jan 03, LEONARD JOHN M sold 19,223 shares at 29.46 per share. NTLA shares that President and CEO owns now total 846,486.
Among the insiders who sold shares, Lebwohl David disposed of 5,843 shares on Jan 03 at a per-share price of $29.46. This resulted in the EVP, Chief Medical Officer holding 54,372 shares of NTLA after the transaction. In another insider transaction, Sepp-Lorenzino Laura sold 5,532 shares at $29.46 per share on Jan 03. Company shares held by the EVP, Chief Scientific Officer now total 46,202.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for NTLA in the last 3 months, the mean price target is $68.74 with high estimates of $144.00 and low estimates of $24.00. In terms of 52-week highs and lows, NTLA has a high of $47.48 and a low of $22.67.
As of this writing, NTLA has an earnings estimate of -$1.38 per share for the current quarter. EPS was calculated based on a consensus of 22 estimates, with a high estimate of -$1.02 per share and a lower estimate of -$1.58. The company reported an EPS of -$1.38 in the last quarter, which was 8.00% higher than expectations of -$1.5.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. NTLA’s latest balance sheet shows that the firm has $748.69M in Cash & Short Term Investments as of fiscal 2021. There were $74.02M in debt and $125.83M in liabilities at the time. Its Book Value Per Share was $11.29, while its Total Shareholder’s Equity was $1.04B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NTLA is Buy with a score of 4.46.
